Developer docs
API playgroundTry for free, no card

Search company profiles

PharmApprove

Full company profile

uuid002mex9

Namestring
PharmApprove
Legal namestring
SSI Strategy LLC
Company typeenum
Private
Founded yearint
1999
Descriptiontext

PharmApprove is a specialized consulting practice focused on high-stakes regulatory and scientific communications for pharmaceutical and biotechnology companies. Operating as the dedicated communications arm of SSI Strategy LLC (legal entity domiciled in New Jersey), the firm provides advisory and presentation support for pivotal regulatory interactions including FDA Advisory Committee meetings, EMA Oral Explanations, and Application Orientation meetings. Founded in 1998, the firm is headquartered in Morristown, New Jersey, and delivers services across North America and Europe.

The firm's service portfolio centers on four offerings: FDA Advisory Committee preparation, EMA Oral Explanation coaching, investor and partner presentation development, and strategic advisory board facilitation. Its methodology follows a structured workflow spanning in-depth gap analysis, narrative workshops, immersive mock rehearsals, final-hour rehearsals, and on-site execution support. The team is built around former FDA and EMA regulators, Key Opinion Leaders, patient advocates, and communications coaches, enabling the firm to bring an insider perspective to high-stakes client engagements.

PharmApprove generates revenue through project-based professional services engagements, with pricing conducted via quote-based proposals rather than publicly disclosed rates. The go-to-market motion is enterprise field sales, with direct engagement via phone, email, and website inquiry forms. The firm maintains a thought leadership presence through multiple podcast series including The Emerging Biotech Leader Podcast, Regulatory: The Emerging C-Suite Leader, and Build Talks, alongside published articles on regulatory strategy and FDA/EMA best practices.

Short descriptiontext

PharmApprove is a specialized regulatory and scientific communications consultancy serving pharmaceutical and biotech sponsors. Operating under SSI Strategy LLC, the firm prepares clients for FDA Advisory Committee meetings, EMA Oral Explanations, and investor presentations using former regulators and KOLs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersEwing Township, United States
HQ citystring
Ewing Township
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regulatory communications consulting, FDA advisory committee preparation, EMA oral explanation coaching, biotech investor presentations, strategic advisory boards
Industry2 codes
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGALAM
KOL Engagement & Medical Education (Advisory Boards/CME Support)
NAICS code1 code
  • Other Management Consulting Services541618
SIC code1 code
  • Services-Management Consulting Services8742
Product category
Pharmaceutical Regulatory Communications Consulting
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Regulatory Advisory Services
TypeProfessional Services
Description

Professional consulting services for FDA Advisory Committee preparation, EMA Oral Explanations, and regulatory strategy. Services include in-depth gap analysis, narrative workshops, immersive mock sessions, and on-site execution support. Revenue is generated through project-based consulting engagements with pharmaceutical and biotech companies.

ssistrategy.com
2Strategic Advisory Boards & Workshops
TypeProfessional Services
Description

Facilitation of tailored advisory boards and KOL workshops for trial designs, regulatory strategies, and commercial launches. Includes curation of expert panels and actionable insight generation.

ssistrategy.com
3Investor & Partner Presentation Services
TypeProfessional Services
Description

Strategic communications support for investor pitches, board briefings, and partner presentations, including data-rich appendices for due diligence.

ssistrategy.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

PharmApprove provides strategic, regulatory, and scientific communications consulting to pharmaceutical and biotech sponsors preparing for high-stakes interactions with regulators, investors, and partners. Core offerings include FDA Advisory Committee preparation, EMA Oral Explanation coaching, investor and partner presentation development, and facilitation of strategic KOL advisory boards and workshops. Engagements are project-based and delivered end-to-end, from gap analysis and narrative workshops through mock rehearsals and on-site execution support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • FDA follows positive committee recommendations in 97% of cases and aligns with panel advice overall 88% of the time
+2 more records
Product overview1 text field

PharmApprove is SSI Strategy's high-stakes communications practice focused on regulatory and investor-facing presentation services. The company offers a unified suite of advisory services including FDA Advisory Committee Preparation, EMA Oral Explanation Preparation, Investor & Partner Presentations, and Strategic Advisory Boards & Workshops. These services work together to help pharmaceutical and biotech companies translate complex science into compelling narratives that drive regulatory approval decisions and secure investor backing.

Product and service5 records
1FDA Advisory Committee Preparation
CategoryRegulatory Communications Consulting
Description

Preparation services for FDA Advisory Committee meetings, including narrative crafting, data presentation, and mock rehearsal sessions to help pharmaceutical and biotech sponsors achieve positive outcomes when facing FDA expert panels.

2EMA Oral Explanation Preparation
CategoryRegulatory Communications Consulting
Description

Preparation for European Medicines Agency Oral Explanations, including 20-minute presentation delivery coaching and slide preparation within the two-day submission window, delivered by experts including former EMA reviewers and scientific advisors.

3Investor & Partner Presentations
CategoryInvestor Communications Consulting
Description

Strategic communications services for investor pitches and partner presentations, distilling scientific depth into persuasive investment theses with data-rich appendices for due diligence support across meetings, pitch contests, and board briefings.

4Strategic Advisory Boards & Workshops
CategoryStrategic Advisory Services
Description

Facilitation of tailored external Key Opinion Leader panels, ex-regulators, and patient advocates to drive smarter trial designs, regulatory strategies, and commercial launches, including high-yield sessions that surface actionable insights and translate them into clear next steps.

5End-to-End High-Stakes Communications
CategoryRegulatory Communications Consulting
Description

Comprehensive support spanning in-depth gap analysis and narrative workshops through immersive mock sessions, final-hour rehearsals, slide-recall hardware, and flawless on-site execution support for regulators, investors, and partners.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Advisory and negotiation consulting firm serving biotech on partnership strategy and stakeholder alignment — partially overlapping with PharmApprove's strategic advisory board and partner presentation services.

TypeBroad incumbent
Description

Life sciences strategy and insights consultancy covering clinical, regulatory, and commercial strategy — a broader incumbent with overlapping scientific communications and launch readiness work.

TypeDirect peer
Description

Healthcare and life sciences consulting firm advising biopharma on strategy, value, and stakeholder communications — overlap with PharmApprove's KOL engagement, evidence translation, and biotech advisory work.

TypeDirect peer
Description

Life sciences strategy and transaction advisory firm with dedicated scientific storytelling and investor presentation services — closely comparable to PharmApprove's investor/partner presentation practice.

TypeBroad incumbent
Description

Global consulting firm with a dedicated life sciences practice serving biopharma on strategy, regulatory economics, and commercial readiness — a broader incumbent with adjacent regulatory and value-communication services.

6Defined Health (now part of Lumanity)
TypeDirect peer
Description

Scientific and medical communications consultancy focused on biotech, helping clients craft narratives for investors, partners, and regulators — overlapping strongly with PharmApprove's investor presentation and strategic advisory offerings.

TypeDirect peer
Description

Regulatory and drug development consultancy offering strategy, submissions, and scientific advice to pharma/biotech — directly comparable to PharmApprove's regulatory strategy and AdCom/Oral Explanation preparation, with overlap in principal experience (notably Laurie Smaldone Alsup's prior tenure).

TypeEmerging player
Description

Pharma and biotech consulting firm offering drug development, regulatory, and commercial strategy — an emerging player with partial overlap in regulatory strategy support for smaller biotech clients.

TypeBroad incumbent
Description

Large life sciences commercialization consultancy offering broad medical communications, evidence, and access services — a broader incumbent with overlapping capabilities in regulatory narrative and scientific communications.

10Scienta Communications
TypeDirect peer
Description

Specializes in FDA Advisory Committee preparation and regulatory communications for pharma/biotech sponsors — a direct competitor on the same core AdCom and oral explanation preparation services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PharmApprove

Pharmaceutical Regulatory Communications Consultingpharmapprove.com

PharmApprove is a specialized regulatory and scientific communications consultancy serving pharmaceutical and biotech sponsors. Operating under SSI Strategy LLC, the firm prepares clients for FDA Advisory Committee meetings, EMA Oral Explanations, and investor presentations using former regulators and KOLs.

What PharmApprove does

PharmApprove is a specialized consulting practice focused on high-stakes regulatory and scientific communications for pharmaceutical and biotechnology companies. Operating as the dedicated communications arm of SSI Strategy LLC (legal entity domiciled in New Jersey), the firm provides advisory and presentation support for pivotal regulatory interactions including FDA Advisory Committee meetings, EMA Oral Explanations, and Application Orientation meetings. Founded in 1998, the firm is headquartered in Morristown, New Jersey, and delivers services across North America and Europe.

The firm's service portfolio centers on four offerings: FDA Advisory Committee preparation, EMA Oral Explanation coaching, investor and partner presentation development, and strategic advisory board facilitation. Its methodology follows a structured workflow spanning in-depth gap analysis, narrative workshops, immersive mock rehearsals, final-hour rehearsals, and on-site execution support. The team is built around former FDA and EMA regulators, Key Opinion Leaders, patient advocates, and communications coaches, enabling the firm to bring an insider perspective to high-stakes client engagements.

PharmApprove generates revenue through project-based professional services engagements, with pricing conducted via quote-based proposals rather than publicly disclosed rates. The go-to-market motion is enterprise field sales, with direct engagement via phone, email, and website inquiry forms. The firm maintains a thought leadership presence through multiple podcast series including The Emerging Biotech Leader Podcast, Regulatory: The Emerging C-Suite Leader, and Build Talks, alongside published articles on regulatory strategy and FDA/EMA best practices.

PharmApprove firmographics

Firmographics
Name
PharmApprove
Legal name
SSI Strategy LLC
Website
https://pharmapprove.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
1–10 employees
Short description
PharmApprove is a specialized regulatory and scientific communications consultancy serving pharmaceutical and biotech sponsors. Operating under SSI Strategy LLC, the firm prepares clients for FDA Advisory Committee meetings, EMA Oral Explanations, and investor presentations using former regulators and KOLs.
Ownership category
akta.pro rank

PharmApprove industry classification

Industry
Product category
Pharmaceutical Regulatory Communications Consulting
NAICS
Other Management Consulting Services (541618)
SIC
Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGALAM
KOL Engagement & Medical Education (Advisory Boards/CME Support)

Keywords

  • Regulatory communications consulting
  • FDA advisory committee preparation
  • EMA oral explanation coaching
  • Biotech investor presentations
  • Strategic advisory boards

Where PharmApprove is headquartered

Location

Headquarters

HQ city
Ewing Township
HQ country
United States
HQ region
North America

Offices1 record

Markets served

PharmApprove business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Regulatory Advisory Services: Professional consulting services for FDA Advisory Committee preparation, EMA Oral Explanations, and regulatory strategy. Services include in-depth gap analysis, narrative workshops, immersive mock sessions, and on-site execution support. Revenue is generated through project-based consulting engagements with pharmaceutical and biotech companies.
  2. Strategic Advisory Boards & Workshops: Facilitation of tailored advisory boards and KOL workshops for trial designs, regulatory strategies, and commercial launches. Includes curation of expert panels and actionable insight generation.
  3. Investor & Partner Presentation Services: Strategic communications support for investor pitches, board briefings, and partner presentations, including data-rich appendices for due diligence.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

PharmApprove product offering

Product offering

Core offering

PharmApprove provides strategic, regulatory, and scientific communications consulting to pharmaceutical and biotech sponsors preparing for high-stakes interactions with regulators, investors, and partners. Core offerings include FDA Advisory Committee preparation, EMA Oral Explanation coaching, investor and partner presentation development, and facilitation of strategic KOL advisory boards and workshops. Engagements are project-based and delivered end-to-end, from gap analysis and narrative workshops through mock rehearsals and on-site execution support.

Product overview

PharmApprove is SSI Strategy's high-stakes communications practice focused on regulatory and investor-facing presentation services. The company offers a unified suite of advisory services including FDA Advisory Committee Preparation, EMA Oral Explanation Preparation, Investor & Partner Presentations, and Strategic Advisory Boards & Workshops. These services work together to help pharmaceutical and biotech companies translate complex science into compelling narratives that drive regulatory approval decisions and secure investor backing.

Differentiator

Problem solved

Functional benefit

Products and services

  • FDA Advisory Committee Preparation Preparation services for FDA Advisory Committee meetings, including narrative crafting, data presentation, and mock rehearsal sessions to help pharmaceutical and biotech sponsors achieve positive outcomes when facing FDA expert panels.
  • EMA Oral Explanation Preparation Preparation for European Medicines Agency Oral Explanations, including 20-minute presentation delivery coaching and slide preparation within the two-day submission window, delivered by experts including former EMA reviewers and scientific advisors.
  • Investor & Partner Presentations Strategic communications services for investor pitches and partner presentations, distilling scientific depth into persuasive investment theses with data-rich appendices for due diligence support across meetings, pitch contests, and board briefings.
  • Strategic Advisory Boards & Workshops Facilitation of tailored external Key Opinion Leader panels, ex-regulators, and patient advocates to drive smarter trial designs, regulatory strategies, and commercial launches, including high-yield sessions that surface actionable insights and translate them into clear next steps.
  • End-to-End High-Stakes Communications Comprehensive support spanning in-depth gap analysis and narrative workshops through immersive mock sessions, final-hour rehearsals, slide-recall hardware, and flawless on-site execution support for regulators, investors, and partners.

Quantifiable outcome

  • FDA follows positive committee recommendations in 97% of cases and aligns with panel advice overall 88% of the time
  • +2 more outcomes

Companies that use PharmApprove

Customer profile

Segments3 records

Ideal customer profiles3 records

PharmApprove technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

PharmApprove partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

PharmApprove competitors and assessment

Company assessment

Emerging players

  • Vantage Partners (Life Sciences): Advisory and negotiation consulting firm serving biotech on partnership strategy and stakeholder alignment — partially overlapping with PharmApprove's strategic advisory board and partner presentation services.
  • Alacrita Consulting: Pharma and biotech consulting firm offering drug development, regulatory, and commercial strategy — an emerging player with partial overlap in regulatory strategy support for smaller biotech clients.

Broad incumbents

  • Trinity Life Sciences: Life sciences strategy and insights consultancy covering clinical, regulatory, and commercial strategy — a broader incumbent with overlapping scientific communications and launch readiness work.
  • Charles River Associates (Life Sciences Practice): Global consulting firm with a dedicated life sciences practice serving biopharma on strategy, regulatory economics, and commercial readiness — a broader incumbent with adjacent regulatory and value-communication services.
  • Lumanity: Large life sciences commercialization consultancy offering broad medical communications, evidence, and access services — a broader incumbent with overlapping capabilities in regulatory narrative and scientific communications.

Direct peers

  • Health Advances: Healthcare and life sciences consulting firm advising biopharma on strategy, value, and stakeholder communications — overlap with PharmApprove's KOL engagement, evidence translation, and biotech advisory work.
  • Back Bay Life Science Advisors: Life sciences strategy and transaction advisory firm with dedicated scientific storytelling and investor presentation services — closely comparable to PharmApprove's investor/partner presentation practice.
  • Defined Health (now part of Lumanity): Scientific and medical communications consultancy focused on biotech, helping clients craft narratives for investors, partners, and regulators — overlapping strongly with PharmApprove's investor presentation and strategic advisory offerings.
  • NDA Group: Regulatory and drug development consultancy offering strategy, submissions, and scientific advice to pharma/biotech — directly comparable to PharmApprove's regulatory strategy and AdCom/Oral Explanation preparation, with overlap in principal experience (notably Laurie Smaldone Alsup's prior tenure).
  • Scienta Communications: Specializes in FDA Advisory Committee preparation and regulatory communications for pharma/biotech sponsors — a direct competitor on the same core AdCom and oral explanation preparation services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

PharmApprove social profiles

Digital presence

PharmApprove financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PharmApprove leadership team

Management profile

Number of profiles

Profiles3 records

PharmApprove funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PharmApprove M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmApprove

What does PharmApprove do?

PharmApprove provides strategic, regulatory, and scientific communications consulting to pharmaceutical and biotech sponsors preparing for high-stakes interactions with regulators, investors, and partners. Core offerings include FDA Advisory Committee preparation, EMA Oral Explanation coaching, investor and partner presentation development, and facilitation of strategic KOL advisory boards and workshops. Engagements are project-based and delivered end-to-end, from gap analysis and narrative workshops through mock rehearsals and on-site execution support.

When was PharmApprove founded?

PharmApprove was founded in 1999. It employs 1 to 10 people.

Where is PharmApprove based?

PharmApprove is headquartered in Ewing Township, United States, in the North America region.

How does PharmApprove make money?

Three revenue lines are on record. Regulatory Advisory Services are the primary driver. The others are strategic Advisory Boards & Workshops and investor & Partner Presentation Services.

Who are PharmApprove's main competitors?

Emerging players on record are Vantage Partners (Life Sciences) and Alacrita Consulting. Broad incumbents are Trinity Life Sciences, Charles River Associates (Life Sciences Practice) and Lumanity. Direct peers are Health Advances, Back Bay Life Science Advisors, Defined Health (now part of Lumanity), NDA Group and Scienta Communications.

Does PharmApprove have an API?

No public API is recorded for PharmApprove.

What industry is PharmApprove in?

PharmApprove's product category is Pharmaceutical Regulatory Communications Consulting. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support, with a secondary code of HLAGALAM, KOL Engagement & Medical Education (Advisory Boards/CME Support). Its NAICS code is 541618 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals